Skip to content

Asset turnover at other companies

ALN
Alnylam PharmaceuticalsALNY
0.9×+0.3×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
0.1×0.0×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
0.0×
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
0.0×
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
0.7×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
0.1×-0.5×

Other financials

Income statement

See full
Revenue-
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$860.66M+295%
Enterprise value$850.62M+313%

Profitability

See full
Operating margin-3,685.8%
Net margin-3,663.7%

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0.0×
Current ratio22.3×-6.1×

Where this comes from

Calculated from Design Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Design Therapeutics, Inc.'s asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Design Therapeutics, Inc.'s asset turnover?
Design Therapeutics, Inc. (DSGN) reported asset turnover of 0× in Q1 2026.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.